Transcriptomic analysis of esophageal tissues and potential
biomarkers for differential diagnostics of Barrett´s mucosa and
esophageal adenocarcinoma

a 2023

Transcriptomic analysis of esophageal tissues and potential biomarkers for differential diagnostics of Barrett´s mucosa and esophageal adenocarcinoma

BOŘILOVÁ LINHARTOVÁ, Petra, Natálie MLČŮCHOVÁ, Jan BÖHM, Petra BRENEROVÁ, Vojtěch BARTOŇ et. al.

Základní údaje

Originální název

Transcriptomic analysis of esophageal tissues and potential biomarkers for differential diagnostics of Barrett´s mucosa and esophageal adenocarcinoma

Autoři

BOŘILOVÁ LINHARTOVÁ, Petra (203 Česká republika, garant, domácí), Natálie MLČŮCHOVÁ (203 Česká republika), Jan BÖHM (203 Česká republika), Petra BRENEROVÁ (203 Česká republika), Vojtěch BARTOŇ (203 Česká republika), Adam MAJER (203 Česká republika), Zdeněk PAVLOVSKÝ (203 Česká republika), Lumír KUNOVSKÝ (203 Česká republika), Radek KROUPA (203 Česká republika), Jiří DOLINA (203 Česká republika), Ondřej URBAN (203 Česká republika), Vít NAVRÁTIL, Tomáš HARUŠTIAK, Robert LISCHKE (203 Česká republika), Tomáš GROLICH (203 Česká republika), Vladimír PROCHÁZKA (203 Česká republika), Lydie IZAKOVIČOVÁ HOLLÁ (203 Česká republika), Martina ZAPLETALOVÁ (203 Česká republika), Jan LOCHMAN (203 Česká republika), Ondřej SLABÝ (203 Česká republika), Eva BUDINSKÁ (703 Slovensko) a Zdeněk KALA (203 Česká republika)

Vydání

Cancer Science, 2023, 2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Japonsko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14310/23:00133535

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Barrett´s esophagus; esophageal adenocarcinoma; CDX2; MUC2; biomarkers; RNAseq

Změněno: 15. 2. 2024 10:20, Mgr. Terezie Slámová

Anotace

V originále

Barrett’s esophagus (BE) is considered a precancerous condition increasing the risk of esophageal adenocarcinoma (EAC) development. This study aimed to find biomarkers with the potential for differential diagnostics of BE and EAC. This pilot study comprised 24 endoscopically examined subjects, namely 12 patients with BE and 12 with EAC. Paired esophageal tissue samples (with the main pathology and adjacent tissue, paraffin-embedded) were histopathologically examined and the presence of CDX2, a diagnostic biomarker for BE//EAC, was immunohistochemically determined using a specific antibody. RNA was isolated from the paired fresh-frozen esophageal tissues, RNAseq library was prepared, and a single-read RNAseq (1x75) was conducted using an Illumina NovaSeq 6000 System. After rRNA removal and mapping to human reference, we obtained 2x 27.5-184 mil. reads per sample. Compared to EAC tissues, we observed a downregulation of the hallmark pathway for angiogenesis and an upregulated hallmark pathway for bile acid metabolism in BE (p<0.01). CDX2 protein and CDX2 gene were highly expressed in tissues with the main pathology in comparison to the adjacent tissue from both BE and EAC patients (p<0.001). On the other hand, the expression of MUC2 (mucin 2) as well as ACER2 (alkaline ceramidase 2) were upregulated in the BE tissue, and among others, TFPI2 (tissue factor pathway inhibitor 2) was downregulated in BE vs EAC tissues (p<0.001). In line with the literature, we confirmed that MUC2 is expressed in BE but not in EAC tissues. It has, therefore, the potential to serve as a biomarker of both differential diagnosis and/or prognosis.

Návaznosti

LM2023069, projekt VaV

Název: Výzkumná infrastruktura RECETOX

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Výzkumná infrastruktura RECETOX

NU20-03-00126, projekt VaV

Název: Hostitelský mikrobiom ve vztahu k rozvoji Barrettova jícnu a adenokarcinomu jícnu

Investor: Ministerstvo zdravotnictví ČR, Hostitelský mikrobiom ve vztahu k rozvoji Barrettova jícnu a adenokarcinomu jícnu, Podprogram 1 - standardní

Citovat

BOŘILOVÁ LINHARTOVÁ, Petra, Natálie MLČŮCHOVÁ, Jan BÖHM, Petra BRENEROVÁ, Vojtěch BARTOŇ, Adam MAJER, Zdeněk PAVLOVSKÝ, Lumír KUNOVSKÝ, Radek KROUPA, Jiří DOLINA, Ondřej URBAN, Vít NAVRÁTIL, Tomáš HARUŠTIAK, Robert LISCHKE, Tomáš GROLICH, Vladimír PROCHÁZKA, Lydie IZAKOVIČOVÁ HOLLÁ, Martina ZAPLETALOVÁ, Jan LOCHMAN, Ondřej SLABÝ, Eva BUDINSKÁ a Zdeněk KALA. Transcriptomic analysis of esophageal tissues and potential biomarkers for differential diagnostics of Barrett´s mucosa and esophageal adenocarcinoma. In Cancer Science, 2023. 2023.

@proceedings{2374118,
   author = {Bořilová Linhartová, Petra and Mlčůchová, Natálie and Böhm, Jan and Brenerová, Petra and Bartoň, Vojtěch and Majer, Adam and Pavlovský, Zdeněk and Kunovský, Lumír and Kroupa, Radek and Dolina, Jiří and Urban, Ondřej and Navrátil, Vít and Haruštiak, Tomáš and Lischke, Robert and Grolich, Tomáš and Procházka, Vladimír and Izakovičová Hollá, Lydie and Zapletalová, Martina and Lochman, Jan and Slabý, Ondřej and Budinská, Eva and Kala, Zdeněk},
   booktitle = {Cancer Science, 2023},
   keywords = {Barrett´s esophagus; esophageal adenocarcinoma; CDX2; MUC2; biomarkers; RNAseq},
   language = {eng},
   title = {Transcriptomic analysis of esophageal tissues and potential biomarkers for differential diagnostics of Barrett´s mucosa and esophageal adenocarcinoma},
   year = {2023}
}

TY  - CONF
ID  - 2374118
AU  - Bořilová Linhartová, Petra - Mlčůchová, Natálie - Böhm, Jan - Brenerová, Petra - Bartoň, Vojtěch - Majer, Adam - Pavlovský, Zdeněk - Kunovský, Lumír - Kroupa, Radek - Dolina, Jiří - Urban, Ondřej - Navrátil, Vít - Haruštiak, Tomáš - Lischke, Robert - Grolich, Tomáš - Procházka, Vladimír - Izakovičová Hollá, Lydie - Zapletalová, Martina - Lochman, Jan - Slabý, Ondřej - Budinská, Eva - Kala, Zdeněk
PY  - 2023
TI  - Transcriptomic analysis of esophageal tissues and potential biomarkers for differential diagnostics of Barrett´s mucosa and esophageal adenocarcinoma
KW  - Barrett´s esophagus
KW  - esophageal adenocarcinoma
KW  - CDX2
KW  - MUC2
KW  - biomarkers
KW  - RNAseq
N2  - Barrett’s esophagus (BE) is considered a precancerous condition increasing the risk of esophageal adenocarcinoma (EAC) development. This study aimed to find biomarkers with the potential for differential diagnostics of BE and EAC. This pilot study comprised 24 endoscopically examined subjects, namely 12 patients with BE and 12 with EAC. Paired esophageal tissue samples (with the main pathology and adjacent tissue, paraffin-embedded) were histopathologically examined and the presence of CDX2, a diagnostic biomarker for BE//EAC, was immunohistochemically determined using a specific antibody. RNA was isolated from the paired fresh-frozen esophageal tissues, RNAseq library was prepared, and a single-read RNAseq (1x75) was conducted using an Illumina NovaSeq 6000 System. After rRNA removal and mapping to human reference, we obtained 2x 27.5-184 mil. reads per sample. Compared to EAC tissues, we observed a downregulation of the hallmark pathway for angiogenesis and an upregulated hallmark pathway for bile acid metabolism in BE (p<0.01). CDX2 protein and CDX2 gene were highly expressed in tissues with the main pathology in comparison to the adjacent tissue from both BE and EAC patients (p<0.001). On the other hand, the expression of MUC2 (mucin 2) as well as ACER2 (alkaline ceramidase 2) were upregulated in the BE tissue, and among others, TFPI2 (tissue factor pathway inhibitor 2) was downregulated in BE vs EAC tissues (p<0.001). In line with the literature, we confirmed that MUC2 is expressed in BE but not in EAC tissues. It has, therefore, the potential to serve as a biomarker of both differential diagnosis and/or prognosis.
ER  -

Podrobný výpis o publikaci